Zilucoplan for Children with Generalized Myasthenia Gravis

We are studying the long-term safety of zilucoplan in children with generalized myasthenia gravis who participated in an earlier trial. This research aims to understand how well the treatment works and its effects over time.

Confirmation phase (III)Post-Trial Drug Access No Placebo Partially Remote Standard Medicines InjectionNeurologyPediatrics

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Zilbrysq

Zilbrysq is a medicine used to treat generalized myasthenia gravis, a disorder that causes muscle weakness and fatigue.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Zilucoplan

Zilucoplan is a substance that blocks part of the immune system to reduce muscle weakness in people with generalized myasthenia gravis.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

IRCCS Foundation Istituto Neurologico Carlo Besta

#40144: Dipartimento Neuroscienze PediatricheSC Neuropsichiatria Infantile – Disordini del Movimento

Milan, Italy

Neurologia Slaska Centrum Medyczne

#40774: Neurologia

Katowice, Poland

Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego

#40218Ș Klinika Neurologii

Ochota, Poland

Sponsor: UCB Biopharma

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.